Palatin supported the underlying research efforts as part of its commitment to developing novel drugs for treating sexual dysfunction, including both female sexual dysfunction and male erectile dysfunction.
Palatin Technologies, Inc. is developing subcutaneously administered bremelanotide for the treatment of female sexual dysfunction and erectile dysfunction in patients non-responsive to current therapies. An at-home Phase 2 clinical trial of subcutaneously administered bremelanotide for pre-menopausal women with female sexual dysfunction is scheduled to start in the current calendar quarter.
About Palatin Technologies, Inc.Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com. SOURCE Palatin Technologies, Inc.